Loading...
As happens every February, approximately 4000 HIV academicians — clinical and basic researchers, along with clinical teachers in HIV medicine — recently gathered for the Conference on Retroviruses and Opportunistic Infections, this year in San Francisco at the Moscone Center. Given the lull in drug development since the approval of etravirine in 2008, the conference featured relatively few clinical trial results on new agents. Indeed, with the success of antiretroviral therapy, the major focus of this meeting has shifted away from the topics listed in the conference name — retroviruses and opportunistic infections — toward the issue of non-AIDS complications. So numerous were the posters and presentations on such complications (including references to cancer and to cardiovascular, renal, and bone disease) that at times, one could forget this was primarily an Infectious Diseases conference!
For the summaries below, our physician-editors have chosen to highlight the conference topics most likely to be useful in clinical practice. Next year's conference will be held in Boston from February 27 to March 3.
Expanding HIV Testing and Treatment
More Data and Answers from AIDS Clinical Trials Group Study 5202
Non–AIDS-Related Adverse Effects of HIV and Its Treatment
Intensification of Antiretroviral Therapy — No Demonstrable Benefit
The Brain, HIV, and Antiretroviral Therapy
CCR5 Antagonists — Out with the Old, In with the New?
2009 H1N1 Influenza and HIV Infection
Randomized Studies of Once-Daily Darunavir and of Tenofovir/FTC + Nevirapine
Hepatitis C Virus and HIV Coinfection: Translating New Discoveries into Clinical Practice